Literature DB >> 28279423

Alternative Biomarkers for Combined Biology.

Yong-Hyun Kim1, Jennifer Kirsop2, Wai Hong Wilson Tang3.   

Abstract

Chemotherapy-related cardiac dysfunction (CRCD) has challenged clinicians to hesitate in using cardiotoxic agents such as anthracycline and several protein kinase inhibitors. As early detection of CRCD and timely cessation of cardiotoxic agents became a strategy to avoid CRCD, cardiac troponin and natriuretic peptide are measured to monitor cardiotoxicity; however, there are inconsistencies in their predictability of CRCD. Alternative biomarkers have been researched extensively for potential use as more sensitive and accurate biomarkers. The mechanisms of CRCD and previous studies on traditional and novel biomarkers for CRCD are examined to enlighten future direction of investigation in this combined biology.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Chemotherapy-related cardiac dysfunction; Heart failure; Malignancy

Mesh:

Substances:

Year:  2017        PMID: 28279423      PMCID: PMC5347470          DOI: 10.1016/j.hfc.2016.12.009

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  120 in total

1.  Multiple biomarkers for risk prediction in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Wayne C Levy; Nancy K Sweitzer; James C Fang; Alan H B Wu; Lee R Goldberg; Mariell Jessup; Thomas P Cappola
Journal:  Circ Heart Fail       Date:  2012-02-23       Impact factor: 8.790

2.  Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.

Authors:  Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi
Journal:  Eur J Heart Fail       Date:  2010-06-05       Impact factor: 15.534

3.  Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?

Authors:  Vedat Köseoğlu; Semha Berberoğlu; Selmin Karademir; Erol Kismet; Neval Yurttutan; Erkan Demirkaya; Metin Sungur; Dursun Alehan
Journal:  Turk J Pediatr       Date:  2005 Jan-Mar       Impact factor: 0.552

4.  Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.

Authors:  Patrick G Morris; Carol Chen; Richard Steingart; Martin Fleisher; Nancy Lin; Beverly Moy; Steven Come; Steven Sugarman; Alyson Abbruzzi; Robert Lehman; Sujata Patil; Maura Dickler; Heather L McArthur; Eric Winer; Larry Norton; Clifford A Hudis; Chau T Dang
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

5.  The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia.

Authors:  J M Horacek; M Vasatova; M Tichy; R Pudil; L Jebavy; J Maly
Journal:  Exp Oncol       Date:  2010-07

6.  Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia.

Authors:  J M Horacek; L Jebavy; M Vasatova; R Pudil; M Tichy; M Jakl; J Maly
Journal:  Bratisl Lek Listy       Date:  2013       Impact factor: 1.278

7.  Validation of putative genomic biomarkers of nephrotoxicity in rats.

Authors:  Er-Jia Wang; Ronald D Snyder; Mark R Fielden; Roger J Smith; Yi-Zhong Gu
Journal:  Toxicology       Date:  2008-01-16       Impact factor: 4.221

8.  Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation.

Authors:  Lubica Roziakova; Eva Bojtarova; Martin Mistrik; Juraj Dubrava; Jozef Gergel; Nadezda Lenkova; Beata Mladosievicova
Journal:  J Exp Clin Cancer Res       Date:  2012-02-09

9.  Trastuzumab Induces an Immediate, Transient Volume Increase in Humans: A Randomised Placebo-Controlled Trial.

Authors:  Joannes A A Reijers; Jacobus Burggraaf
Journal:  EBioMedicine       Date:  2015-05-08       Impact factor: 8.143

10.  Clinical significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients.

Authors:  Yinghuan Ma; Wanjun Kang; Yongxin Bao; Fubin Jiao; Yiran Ma
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more
  1 in total

Review 1.  Protecting the heart in cancer therapy.

Authors:  J Emanuel Finet; W H Wilson Tang
Journal:  F1000Res       Date:  2018-09-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.